共 119 条
[1]
Massi-Benedetti M(1999)Cardiovascular risk factors in type 2 diabetes: the role of hyperglycaemia Exp Clin Endocrinol Diabetes 107 S120-S123
[2]
Federici MO(2002)High glucose-induced activation of protein kinase signaling pathways in vascular smooth muscle cells: a potential role in the pathogenesis of vascular dysfunction in diabetes Int J Mol Med 9 85-89
[3]
Srivastava AK(2006)Therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients Diabetes Care 29 554-559
[4]
Rosenstock J(2005)Rosiglitazone improves exercise capacity in individuals with type 2 diabetes Diabetes Care 28 2877-2883
[5]
Sugimoto D(2008)Beneficial effects of Rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus Diabet Med 25 333-340
[6]
Strange P(2002)Improvement of aortic wall distensibility and reduction of oxidative stress by pioglitazone in pre-diabetic stage of Otsuka Long–Evans Tokushima fatty rats Cardiovasc Drugs Ther 16 429-434
[7]
Stewart J(2004)Effects of rosiglitazone on blood glucose, blood lipid and vascular remodeling in rats fed with high fructose diet Chin Pharmacol Bull 20 571-575
[8]
Erika SR(2003)Effect of peroxisome proliferator-activated receptor-a and -g activators on vascular remodeling in endothelin-dependent hypertension Arterioscler Thromb Vasc Biol 23 45-51
[9]
Dailey G(2005)PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells Atherosclerosis 183 163-167
[10]
Regensteiner JG(2005)Effects of rosiglitazone on aortic function in rats with insulin resistant-hypertension Sheng Li Xue Bao 57 125-131